Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan in Children With Relapsed Solid Tumors
NCT00003745Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 1999
- Primary completion
- Jun 2003
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of topotecan in sarcoma, brain tumor and neuroblastoma, sponsored by National Cancer Institute. Primary endpoints: Response Rate and Toxicity. Started May 1999; status: completed.
02
Drugs
topotecan
03
Conditions
sarcomabrain tumorneuroblastoma
Beyond the preview
Go deeper on NCT00003745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003745.